| 项目编号 |
PRJCA022768 |
| 项目标题 |
A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early-stage resectable hepatocellular carcinoma |
| 涉及领域 |
Medical |
| 数据类型 |
Targeted Locus (Loci)
Transcriptome or Gene expression
Raw sequence reads
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
Neoadjuvant therapy of ICIs plus stereotactic body radiotherapy (SBRT) has shown promising results in several types of solid tumours but not HCC.This is a phase Ib clinical trial of neoadjuvant SBRT plus PD-1 (tislelizumab) in HCC patients (pts). Prior to resection, pts receive 8 Gy x 3 fractions of SBRT together with 2 cycles of PD-1 with an interval of 3 weeks. HCC resection is scheduled 4 weeks after the second dose of PD-1, followed by adjuvant PD-1 for up to 1 year. We plan to enrol 20 participants in this trial. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2024-01-23 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 38627377
|
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
|
Nature Communications
|
10.1038/s41467-024-47420-3
|
2024
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| National Natural Science Foundation of China (NSFC)
|
General Program
|
81872400and81472713and81272375
|
|
| Shandong Natural Scientific Fund
|
The Key Research and Development Program
|
2021SFGC0501
|
|
| Shandong Natural Scientific Fund
|
Joint Innovation and Development Item
|
ZR2021LZL008
|
|
|
|
| 提交者 |
Lei
Zhao (drzhaolei@hotmail.com)
|
| 提交单位 |
Shan dong cancer hospital |
| 提交日期 |
2024-01-11 |
